Merck secures Japanese approval for subcutaneous Keytruda

RegulatoryapprovedKeytrudaPositive

AI Analysis

Summary

Merck has secured Japanese regulatory approval for a subcutaneous formulation of Keytruda (pembrolizumab), expanding the drug's delivery options in the Japanese market.

Outcome Details

Japanese approval for subcutaneous Keytruda

Importance:6/10

Sentiment:

0.70

regulatory approvalJapanKeytrudasubcutaneous formulation

Related Companies

$MRK

Read the original article

Published by Seeking Alpha Healthcare on September 21, 2026 12:17 PM

Read Original